Boston Scientific Corp (BSX) is undervalued and GE HealthCare Technologies Inc (GEHC) is undervalued.
Against our estimates of intrinsic value, BSX trades at the wider discount: a margin of safety of +30%, against +29% for GEHC.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 8.0% (average of 3 methods) values the shares at $64.12; the price of $44.92 is 30% below that value, and 80% of that value comes from beyond year five.
Leak Score 73/100 on 10 of 12 signals
Discounting its cash flows at 9.1% (average of 3 methods) values the shares at $93.41; the price of $66.27 is 29% below that value, and 75% of that value comes from beyond year five.
Leak Score 63/100 on 5 of 12 signals
| Metric | BSX | GEHC |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Price | $44.92 | $66.27 |
| Intrinsic value | $64.12 | $93.41 |
| Margin of safety | +30% | +29% |
| Leak Score | 73/100 (10/12) | 63/100 (5/12) |
| Market cap | $65.1B | $29.9B |
| Revenue growth, 5 years | 15.2% | 3.7% |
| Operating margin | 21.8% | 13.7% |
| Net margin | 17.5% | 9.3% |
| Return on equity | 15.5% | 19.2% |
| Debt to equity | 0.51 | 0.96 |
| P/E | 18.2x | 15.2x |
| Forward P/E | 13.2x | 12.2x |
| P/B | 2.6x | 2.7x |
| Dividend yield | — | 0.2% |